Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment

Journal of Medical Virology

Volumn 80, Issue 8, 2008, Pages 1434-1440

  Venturoli, Simona ^a,b   Ambretti, Simone ^a   Cricca, Monica ^a   Leo, Elisa ^a   Costa, Silvano ^b   Musiani, Monica ^a   Zerbini, Marialuisa ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Follow up; HPV genotyping; HR HPV persistence; Residual or recurrent disease

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL EVALUATION; CYTOLOGY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LINEAR ARRAY HPV GENOTYPING TEST; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RECURRENT DISEASE; UTERINE CERVIX CANCER; VIRUS DETECTION; WART VIRUS;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CONIZATION; FEMALE; GENOTYPE; HUMANS; INCIDENCE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RECURRENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 46049101421     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21198     Document Type: Article

References (32)

1. Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Campo E, Pahisa J, Ordi J. 2006. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN2-3. Gynecol Oncol 103:631-636.
2. Bar-Am A, Gamzu R, Levin I, Fainaru O, Niv J, Almog B. 2003. Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up. Gynecol Oncol 91:149-153.
3. Bodner K, Bodner-Adler B, Wierrani F, Kimberger O, Denk C, Grunberger W. 2002. Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis. Anticancer Res 22:3733-3736.
4. Bollen LJ, Tjong AHSP, van der Velden J, Mol BW, Boer K, ten Kate FJ, Bleker OP, ter Schegget J. 1997. Clearance of cervical human papillomavirus infection by treatment for cervical dysplasia. Sex Transm Dis 24:456-460.
5. Boyle P, Leon ME, Maisonneuve P, Autier P. 2003. Cancer control in women. Int J Gynecol Obstet 83:179-202.
6. Chaturvedi AK, Myers L, Hammons AF, Clark RA, Dunlap K, Kissinger PJ, Hagensee ME. 2005. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev 14:2439-2445.
7. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. 2001. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84:1616-1623.
8. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88:63-73.
9. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. 2005. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14:1157-1164. (Review).
10. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. 2006. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24:S26-S34.
11. Costa S, De Nuzzo M, Terzano P, Santini D, De Simone P, Bovicelli A, Bovicelli L, Bucchi L. 2000. Factors associated with cone margin involvement in CIN patients undergoing conization-equivalent electrosurgical procedure. Acta Obstet Gynecol Scand 79:586-592.
12. Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M, Terzano P, Santini D, Cristiani P, Syrjanen S, Syrjanen K. 2003. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol 90:358-365.
13. Costa S, Negri G, Sideri M, Santini D, Martinelli G, Venturoli S, Pelusi C, Syrjanen S, Syrjanen K, Pelusi G. 2007. Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol 106:170-176.
14. Cricca M, Venturoli S, Morselli-Labate AM, Costa S, Santini D, Ambretti S, Musiani M, Zerbini M. 2006. HPV DNA patterns and disease implications in the follow-up of patients treated for HPV16 high-grade carcinoma in situ. J Med Virol 78:494-500.
15. Cricca M, Morselli-Labate AM, Venturoli S, Ambretti S, Gentilomi GA, Gallinella G, Costa S, Musiani M, Zerbini M. 2007. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol 106:549-557.
16. Fen J, Yoshinouchi M, Nakamura K, Kodama J, Nasu Y, Yamato K, Hiramatsu Y. 2004. Eradication of HPV post-surgical treatments, its correlation with specific types, types of surgery and the physical status. Oncol Rep 12:375-379.
17. Gargiulo F, De Francesco MA, Schreiber C, Ciravolo G, Salinaro F, Valloncini B, Manca N. 2007. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res 125:176-182.
18. Houfflin Debarge V, Collinet P, Vinatier D, Ego A, Dewilde A, Boman F, Leroy JL. 2003. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecol Oncol 90:587-592.
19. Jain S, Tseng CJ, Horng SG, Soong YK, Pao CC. 2001. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynecol Oncol 82:177-180.
20. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, Wheeller CM, Castle PE. the ALTS Group. 2006. HPV testing following loop electrosurgical excision procedure (LEEP) identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 15:908-914.
21. Kreimer AR, Katki HA, Schiffman M, Wheeler CM, Castle PE. the ALTS Group. 2007. Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3. Cancer Epidemiol Biomarkers Prev 16:11-16.
22. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
23. Nagai Y, Maehama T, Asato T, Kanazawa K. 2000. Persistence of human papillomavirus infection after therapeutic conization for CIN 3:Is it an alarm for disease recurrence? Gynecol Oncol 79:294-299.
24. Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, Verheijen RH, Helmerhorst TJ. 2001. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 84:796-801.
25. Nuovo G, Moritz J, Kowalik A, Chalas E, Kaplan B, Mann W. 1992. Human papillomavirus types and cervical squamous intraepithelial lesions that recur after cold-knife conization. Gynecol Oncol 46:304-308.
26. Ordi J, Alonso I, Torné A, Esteve R, Sierra E, Campo E, Puig-Tintore LM. 2005. Human papillomavirus load in hybrid capture 2 assay: does increasing the cutoff improve the test? Gynecol Oncol 99:313-319.
27. Sarian LO, Derchain SF, Pittal Dda R, Morais SS, Rabelo-Santos SH. 2004. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). J Clin Virol 31:270-274.
28. Stevens MP, Tabrizi SN, Quinn MA, Garland SM. 2006. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia Int J Ginecol Cancer 16:1017-1024.
29. Tyler LN, Andrews N, Parrish RS, Hazlett LJ, Korourian S. 2007. Significance of margin and extent of dysplasia in loop electrosurgery excision procedure biopsies performed for high-grade squamous intraepithelial lesion in predicting persistent disease. Arch Pathol Lab Med 131:622-624.
30. van Ham MA, van Hamont D, Bekkers RL, Bulten J, Melchers WJ, Massuger LF. 2007. High-risk HPV presence in cervical specimens after a large loop excision of the cervical transformation zone: significance of newly detected hr-HPV genotypes. J Med Virol 79:314-319.
31. van Hamont D, van Ham MA, Bakkers JM, Massuger LF, Melchers WJ. 2006. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche Linear Array HPV Genotyping Test. J Clin Microbiol 44:3122-3129.
32. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ. 2004. HPV testing and monitoring of women after treatment of CIN. 3. Review of the literature and meta-analysis. Obstet Gynecol Surv 59:543-553.